189 related articles for article (PubMed ID: 12065435)
1. The pharmacokinetics of a thiazole benzenesulfonamide beta 3-adrenergic receptor agonist and its analogs in rats, dogs, and monkeys: improving oral bioavailability.
Stearns RA; Miller RR; Tang W; Kwei GY; Tang FS; Mathvink RJ; Naylor EM; Chitty D; Colandrea VJ; Weber AE; Colletti AE; Strauss JR; Keohane CA; Feeney WP; Iliff SA; Chiu SH
Drug Metab Dispos; 2002 Jul; 30(7):771-7. PubMed ID: 12065435
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.
Mathvink RJ; Tolman JS; Chitty D; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Miller RR; Stearns RA; Tota L; Wyvratt MJ; Fisher MH; Weber AE
J Med Chem; 2000 Oct; 43(21):3832-6. PubMed ID: 11052788
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of a thiazole benzenesulfonamide derivative, a potent and elective agonist of the human beta3-adrenergic receptor, in rats: identification of a novel isethionic acid conjugate.
Tang W; Stearns RA; Miller RR; Ngui JS; Mathvink RJ; Weber AE; Kwei GY; Strauss JR; Keohane CA; Doss GA; Chiu SH; Baillie TA
Drug Metab Dispos; 2002 Jul; 30(7):778-87. PubMed ID: 12065436
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
5. Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.
Feng DD; Biftu T; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Miller RR; Stearns RA; Strader CD; Tota L; Wyvratt MJ; Fisher MH; Weber AE
Bioorg Med Chem Lett; 2000 Jul; 10(13):1427-9. PubMed ID: 10888324
[TBL] [Abstract][Full Text] [Related]
6. Beta(3)-adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys.
Hom GJ; Forrest MJ; Bach TJ; Brady E; Candelore MR; Cascieri MA; Fletcher DJ; Fisher MH; Iliff SA; Mathvink R; Metzger J; Pecore V; Saperstein R; Shih T; Weber AE; Wyvratt M; Zafian P; MacIntyre DE
J Pharmacol Exp Ther; 2001 Apr; 297(1):299-307. PubMed ID: 11259557
[TBL] [Abstract][Full Text] [Related]
7. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men.
van Baak MA; Hul GB; Toubro S; Astrup A; Gottesdiener KM; DeSmet M; Saris WH
Clin Pharmacol Ther; 2002 Apr; 71(4):272-9. PubMed ID: 11956510
[TBL] [Abstract][Full Text] [Related]
8. 3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.
Weber AE; Ok HO; Alvaro RF; Candelore MR; Cascieri MA; Chiu SH; Deng L; Forrest MJ; Hom GJ; Hutchins JE; Kao J; MacIntyre DE; Mathvink RJ; McLoughlin D; Miller RR; Newbold RC; Olah TV; Parmee ER; Perkins L; Stearns RA; Strader CD; Szumiloski J; Tang YS; Tota L; Fisher MH
Bioorg Med Chem Lett; 1998 Aug; 8(16):2111-6. PubMed ID: 9873496
[TBL] [Abstract][Full Text] [Related]
9. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
10. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
11. Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.
Parmee ER; Naylor EM; Perkins L; Colandrea VJ; Ok HO; Candelore MR; Cascieri MA; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Miller RR; Stearns RA; Strader CD; Tota L; Wyvratt MJ; Fisher MH; Weber AE
Bioorg Med Chem Lett; 1999 Mar; 9(5):749-54. PubMed ID: 10201841
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
13. Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.
Brockunier LL; Parmee ER; Ok HO; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Tota L; Wyvratt MJ; Fisher MH; Weber AE
Bioorg Med Chem Lett; 2000 Sep; 10(18):2111-4. PubMed ID: 10999482
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences.
Roller S; Cui D; Laspina C; Miller-Stein C; Rowe J; Wong B; Prueksaritanont T
Xenobiotica; 2009 Jan; 39(1):33-45. PubMed ID: 19219746
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 2nd communication: Absorption and excretion in rabbits, dogs and monkeys after a single administration of 14C-NS-49.
Mukai H; Watanabe S; Morino A
Arzneimittelforschung; 1999 Jun; 49(6):527-32. PubMed ID: 10417870
[TBL] [Abstract][Full Text] [Related]
16. Physiological disposition of L-663,581, a partial agonist of the benzodiazepine receptor, in laboratory animals.
Chen IW; Lin JH
Drug Metab Dispos; 1994; 22(5):693-9. PubMed ID: 7835219
[TBL] [Abstract][Full Text] [Related]
17. Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys.
Lin CC; Luu T; Lourenco D; Yeh LT; Lau JY
J Antimicrob Chemother; 2003 Jan; 51(1):93-9. PubMed ID: 12493792
[TBL] [Abstract][Full Text] [Related]
18. The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor.
Sato M; Hutchinson DS; Evans BA; Summers RJ
Mol Pharmacol; 2008 Nov; 74(5):1417-28. PubMed ID: 18684840
[TBL] [Abstract][Full Text] [Related]
19. Disposition of a novel and potent alpha(v)beta3 antagonist in animals, and extrapolation to man.
Prueksaritanont T; Fernandez-Metzler C; Meng Y; Barrish A; Halczenko W; Rodan SB; Hutchinson JH; Duggan ME; Lin JH
Xenobiotica; 2004 Jan; 34(1):103-15. PubMed ID: 14742139
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.
Biftu T; Feng DD; Liang GB; Kuo H; Qian X; Naylor EM; Colandrea VJ; Candelore MR; Cascieri MA; Colwell LF; Forrest MJ; Hom GJ; MacIntyre DE; Stearns RA; Strader CD; Wyvratt MJ; Fisher MH; Weber AE
Bioorg Med Chem Lett; 2000 Jul; 10(13):1431-4. PubMed ID: 10888325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
